Select a category to explore research frontiers
Loading categories...
Development of patient-specific neoantigen vaccines and engineered cell therapies based on individual tumor mutational landscapes.
Current approaches fail to identify why neoantigen-reactive T cells become dysfunctional in cold tumors despite personalized neoantigen vaccine design. This research gap addresses the mechanisms underlying T cell exhaustion in low-immunogenic tumor microenvironments and how to reverse it through rational combination therapies.
Existing HLA-peptide prediction algorithms are trained predominantly on common HLA alleles, leaving 70% of rare HLA combinations unexplored. This frontier addresses developing personalized binding prediction models for ethnically diverse populations with underrepresented HLA genotypes.
Current CAR-T monitoring relies on bulk sequencing and flow cytometry, missing spatial and temporal clonal dynamics within tumor microenvironments. This research gap focuses on integrating spatial transcriptomics to track individual CAR-T clones in real-time and predict treatment failure before clinical deterioration.
Despite uniform checkpoint inhibitor dosing, response rates vary dramatically due to unmapped patient-specific cytokine dysregulation patterns. This frontier addresses integrating systems immunology approaches to model individual cytokine network architecture and predict responders before treatment initiation.
Current in vitro immunotherapy screening uses immortalized cell lines lacking patient-specific immune cell composition and tumor architecture. This gap addresses developing personalized organoid platforms that recapitulate individual patient immune infiltrate biology for rapid, ex vivo immunotherapy optimization.
Emerging evidence shows microbiome composition predicts checkpoint inhibitor and neoantigen vaccine response, yet mechanistic links through bacterial metabolites remain opaque. This frontier addresses identifying patient-specific bacterial metabolite signatures and testing personalized microbiota engineering strategies.
Current neoantigen vaccine designs assume uniform T cell expansion capacity, but patient epigenetic architecture determines TCR repertoire diversity and functional T cell avidity. This gap addresses single-cell epigenomic profiling to predict which patients will generate oligoclonal versus polyclonal anti-tumor responses.
Tertiary lymphoid structures (TLS) emerge during immunotherapy response, yet patient capacity for TLS formation is unexplored and not integrated into treatment selection. This frontier addresses identifying patient-specific TLS formation potential and engineering strategies to induce their development in TLS-deficient tumors.